Heparin induces rat aorta relaxation via integrin-dependent activation of muscarinic M3 receptors

Hypertension

Volumn 56, Issue 4, 2010, Pages 713-721

  Paredes Gamero, Edgar J ^a   Medeiros, Valquíria P ^a   Farias, Eduardo H C ^a   Justo, Giselle Z ^a   Trindade, Edvaldo S ^b   Andrade Lopes, Ana L ^a   Godinho, Rosely O ^a   De Miranda, Antonio ^a   Ferreira, Alice T ^a   Tersariol, Ivarne L S ^a   Nader, Helena B ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

1,1, DIMETHYL 4 DIPHENYLACETOXYPIPERIDINIUM IODIDE INHIBITOR; ATROPINE; ENOXAPARIN; FOCAL ADHESION KINASE; HEPARIN; INTEGRIN; MUSCARINIC M2 RECEPTOR ANTAGONIST; MUSCARINIC M3 RECEPTOR; PAXILLIN; SURAMIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; ENDOTHELIUM; ENZYME ACTIVATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; VASODILATATION;

ACETYLCHOLINE; ANIMALS; ANTICOAGULANTS; AORTA, THORACIC; ATROPINE; BLOTTING, WESTERN; CATTLE; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEPARIN; INTEGRINS; MALE; NITRIC OXIDE; OLIGOPEPTIDES; PAXILLIN; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RATS; RATS, WISTAR; RECEPTOR, MUSCARINIC M3; VASODILATION; VASODILATOR AGENTS;

EID: 77957224404     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.156877     Document Type: Article

References (55)

1. Nader HB, Pinhal MA, Bau EC, Castro RA, Medeiros GF, Chavante SF, Leite EL, Trindade ES, Shinjo SK, Rocha HA, Tersariol IL, Mendes A, Dietrich CP. Development of new heparin-like compounds and other antithrombotic drugs and their interaction with vascular endothelial cells. Braz J Med Biol Res. 2001;34:699-709. (Pubitemid 32613084)
2. Fareed J, Jeske W, Fareed D, Clark M, Wahi R, Adiguzel C, Hoppensteadt D. Are all low molecular weight heparins equivalent in the management of venous thromboembolism? Clin Appl Thromb Hemost. 2008; 14:385-392.
3. Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol. 2001;21:1094-1096. (Pubitemid 34215133)
4. Silva ME, Dietrich CP. Structure of heparin: characterization of the products formed from heparin by the action of a heparinase and a heparitinase from Flavobacterium heparinum. J Biol Chem. 1975;250: 6841-6846.
5. Silva ME, Dietrich CP. Studies on the induction of heparin degrading enzymes in Flavobacterium heparinum: II-structural requirements of the inducer. Biochimie. 1973;55:1101-1106.
6. Lane DA, Ryan K. Heparin and low molecular weight heparin: is antifactor Xa activity important? J Lab Clin Med. 1989;114:331-333. (Pubitemid 19253264)
7. Vaheri A. Heparin and related polyionic substances as virus inhibitors. Acta Pathol Microbiol Scand. 1964;171(suppl):171-198.
8. Corrigan JJ Jr. Heparin therapy in bacterial septicemia. J Pediatr. 1977; 91:695-700. (Pubitemid 8207585)
9. Nader HB, Toma L, Pinhal MA, Buonassisi V, Colburn P, Dietrich CP. Effect of heparin and dextran sulfate on the synthesis and structure of heparan sulfate from cultured endothelial cells. Semin Thromb Hemost. 1991;17(suppl):47-56.
10. Trindade ES, Oliver C, Jamur MC, Rocha HA, Franco CR, Boucas RI, Jarrouge TR, Pinhal MA, Tersariol IL, Gouvea TC, Dietrich CP, Nader HB. The binding of heparin to the extracellular matrix of endothelial cells up-regulates the synthesis of an antithrombotic heparan sulfate proteoglycan. J Cell Physiol. 2008;217:328-337.
11. Trindade ES, Boucas RI, Rocha HA, Dominato JA, Paredes-Gamero EJ, Franco CR, Oliver C, Jamur MC, Dietrich CP, Nader HB. Internalization and degradation of heparin is not required for stimulus of heparan sulfate proteoglycan synthesis. J Cell Physiol. 2008;217:360-366.
12. Tersariol IL, Dietrich CP, Nader HB. Interaction of heparin with myosin ATPase: possible involvement with the hemorrhagic activity and a correlation with antithrombin III high affinity-heparin molecules. Thromb Res. 1992;68:247-258.
13. Yamamoto H, Kanaide H, Nakamura M. Heparin specifically inhibits the inositol 1,4,5-trisphosphate-induced Ca2- release from skinned rat aortic smooth muscle cells in primary culture. Naunyn Schmiedebergs Arch Pharmacol. 1990;341:273-278. (Pubitemid 20137879)
14. Shinjo SK, Tersariol IL, Oliveira V, Nakaie CR, Oshiro ME, Ferreira AT, Santos IA, Dietrich CP, Nader HB. Heparin and heparan sulfate disaccharides bind to the exchanger inhibitor peptide region of Na-/Ca2 exchanger and reduce the cytosolic calcium of smooth muscle cell lines: requirement of C4-C5 unsaturation and 1-4 glycosidic linkage for activity. J Biol Chem. 2002;277:48227-48233. (Pubitemid 35470774)
15. Waser P, Keller R. Hypotensive effect of heparin [in German]. Helv Physiol Pharmacol Acta. 1954;12:C94-C98.
16. Keller R. Experimental studies on the hypotensive effect of heparin: I. Arch Int Pharmacodyn Ther. 1956;107:382-396.
17. Kongsgaard UE, Smith-Erichsen N, Hysing E, Tollofsrud S, Seem E, Geiran O, Bjornskau L. Haemodynamic effects of heparin during coronary bypass surgery. Acta Anaesthesiol Scand. 1991;35:758-761.
18. Kutyrina IM, Nikishova TA, Tareeva IE. Hypotensive and diuretic effect of heparin in patients with glomerulonephritis. Ter Arkh. 1985;57:78-81. (Pubitemid 15042426)
19. Abbott EC, Gornall AG, Sutherland DJ, Laidlaw JC, Stiefel M. The influence of a heparin-like compound on hypertension, electrolytes and aldosterone in man. Can Med Assoc J. 1966;94:1155-1164.
20. Wilson SK, Solez K, Boitnott JK, Heptinstall RH. The effects of heparin treatment on hypertension and vascular lesions in stroke-prone spontaneously hypertensive rats. Am J Pathol. 1981;102:62-71. (Pubitemid 11142817)
21. Susic D, Mandal AK, Kentera D. Heparin lowers the blood pressure in hypertensive rats. Hypertension. 1982;4:681-685. (Pubitemid 13239686)
22. Kentera D, Susic D, Zdravkovic M. Hypotensive effect of heparin on experimental chronic pulmonary hypertension in rats. Basic Res Cardiol. 1985;80:142-146. (Pubitemid 15098182)
23. Yokokawa K, Mankus R, Saklayen MG, Kohno M, Yasunari K, Minami M, Kano H, Horio T, Takeda T, Mandel AK. Increased nitric oxide production in patients with hypotension during hemodialysis. Ann Intern Med. 1995;123:35-37.
24. Kouretas PC, Hannan RL, Kapur NK, Hendrickson R, Redmond EM, Myers AK, Kim YD, Cahill PA, Sitzmann JV. Non-anticoagulant heparin increases endothelial nitric oxide synthase activity: role of inhibitory guanine nucleotide proteins. J Mol Cell Cardiol. 1998;30:2669-2682. (Pubitemid 29017507)
25. Buzun L, Kleszczewski T, Kostrzewska A, Lisowski P, Oleksza P, Jackowski R, Pedzinska A, Hirnle T. Influence of low molecular weight heparin preparations on human internal thoracic artery contraction. Eur J Cardiothorac Surg. 2004;26:951-955. (Pubitemid 39433878)
26. Khurana S, Chacon I, Xie GF, Yamada M, Wess J, Raufman JP, Kennedy RH. Vasodilatory effects of cholinergic agonists are greatly diminished in aorta from M3R(-/-) mice. Eur J Pharmacol. 2004;493:127-132.
27. Fazio MA, Oliveira VX Jr, Bulet P, Miranda MT, Daffre S, Miranda A. Structure-activity relationship studies of gomesin: importance of the disulfide bridges for conformation, bioactivities, and serum stability. Biopolymers. 2006;84:205-218.
28. Milani R, Ferreira CV, Granjeiro JM, Paredes-Gamero EJ, Silva RA, Justo GZ, Nader HB, Galembeck E, Peppelenbosch MP, Aoyama H, Zambuzzi WF. Phosphoproteome reveals an atlas of protein signaling networks during osteoblast adhesion. J Cell Biochem. 2010;109:957-966.
29. Ecke D, Hanck T, Tulapurkar ME, Schafer R, Kassack M, Stricker R, Reiser G. Hetero-oligomerization of the P2Y11 receptor with the P2Y1 receptor controls the internalization and ligand selectivity of the P2Y11 receptor. Biochem J. 2008;409:107-116.
30. De Angelis A, Rinaldi B, Capuano A, Rossi F, Filippelli A. Indomethacin potentiates acetylcholine-induced vasodilation by increasing free radical production. Br J Pharmacol. 2004;142:1233-1240. (Pubitemid 39178876)
31. Kojima H, Nakatsubo N, Kikuchi K, Kawahara S, Kirino Y, Nagoshi H, Hirata Y, Nagano T. Detection and imaging of nitric oxide with novel fluorescent indicators: diaminofluoresceins. Anal Chem. 1998;70: 2446-2453. (Pubitemid 128501019)
32. Ureshino RP, Bertoncini CR, Fernandes MJ, Abdalla FM, Porto CS, Hsu YT, Lopes GS, Smaili SS. Alterations in calcium signaling and a decrease in Bcl-2 expression: possible correlation with apoptosis in aged striatum. J Neurosci Res. 2010;88:438-447.
33. Furlan I, Godinho RO. Developing skeletal muscle cells express functional muscarinic acetylcholine receptors coupled to different intracellular signaling systems. Br J Pharmacol. 2005;146:389-396. (Pubitemid 41486681)
34. Hansmann G, Bultmann R, Tuluc F, Starke K. Characterization by antagonists of P2-receptors mediating endothelium-dependent relaxation in the rat aorta. Naunyn Schmiedebergs Arch Pharmacol. 1997;356: 641-652. (Pubitemid 27478968)
35. Guan JL. Role of focal adhesion kinase in integrin signaling. Int J Biochem Cell Biol. 1997;29:1085-1096. (Pubitemid 27511719)
36. Hirsh J, Anand SS, Halperin JL, Fuster V. AHA Scientific Statement: guide to anticoagulant therapy- heparin: a statement for healthcare professionals from the American Heart Association. Arterioscler Thromb Vasc Biol. 2001;21:E9-E9. (Pubitemid 32578141)
37. Nader HB, Lopes CC, Rocha HA, Santos EA, Dietrich CP. Heparins and heparinoids: occurrence, structure and mechanism of antithrombotic and hemorrhagic activities. Curr Pharm Des. 2004;10:951-966.
38. Carrillo P, Milanes-Lopez B, Mc CG. Vasodilation and regional heparinization by arterial catheterization in peripheral vascular disorders. Angiology. 1957;8:537-541.
39. Tasatargil A, Golbasi I, Sadan G, Karasu E. Unfractioned heparin produces vasodilatory action on human internal mammary artery by endothelium-dependent mechanisms. J Cardiovasc Pharmacol. 2005;45: 114-119. (Pubitemid 40170673)
40. Tasatargil A, Ogutman C, Golbasi I, Karasu E, Dalaklioglu S. Comparison of the vasodilatory effect of nadroparin, enoxaparin, dalteparin, and unfractioned heparin in human internal mammary artery. J Cardiovasc Pharmacol. 2005;45:550-554. (Pubitemid 40734576)
41. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:188S-203S. (Pubitemid 39297954)
42. Cardin AD, Weintraub HJ. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis. 1989;9:21-32.
43. Li JH, Han SJ, Hamdan FF, Kim SK, Jacobson KA, Bloodworth LM, Zhang X, Wess J. Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands. J Biol Chem. 2007;282:26284-26293. (Pubitemid 47443813)
44. Deprez P, Inestrosa NC, Krejci E. Two different heparin-binding domains in the triple-helical domain of ColQ, the collagen tail subunit of synaptic acetylcholinesterase. J Biol Chem. 2003;278:23233-23242. (Pubitemid 36830136)
45. Slack BE. Tyrosine phosphorylation of paxillin and focal adhesion kinase by activation of muscarinic m3 receptors is dependent on integrin engagement by the extracellular matrix. Proc Natl Acad Sci U S A. 1998; 95:7281-7286.
46. Gutkind JS, Robbins KC. Activation of transforming G protein-coupled receptors induces rapid tyrosine phosphorylation of cellular proteins, including p125FAK and the p130 v-src substrate. Biochem Biophys Res Commun. 1992;188:155-161.
47. Petryniak MA, Wurtman RJ, Slack BE. Elevated intracellular calcium concentration increases secretory processing of the amyloid precursor protein by a tyrosine phosphorylation-dependent mechanism. Biochem J. 1996;320:957-963.
48. Tsai W, Morielli AD, Peralta EG. The m1 muscarinic acetylcholine receptor transactivates the EGF receptor to modulate ion channel activity. EMBO J. 1997;16:4597-4605. (Pubitemid 27326597)
49. Rosado JA, Salido GM, Garcia LJ. Activation of m3 muscarinic receptors induces rapid tyrosine phosphorylation of p125(FAK), p130(cas), and paxillin in rat pancreatic acini. Arch Biochem Biophys. 2000;377:85-94.
50. Barkalow FJ, Schwarzbauer JE. Localization of the major heparinbinding site in fibronectin. J Biol Chem. 1991;266:7812-7818.
51. Mitchell G, Lamontagne CA, Lebel R, Grandbois M, Malouin F. Singlemolecule dynamic force spectroscopy of the fibronectin-heparin interaction. Biochem Biophys Res Commun. 2007;364:595-600. (Pubitemid 350030923)
52. Maile LA, Aday AW, Busby WH, Sanghani R, Veluvolu U, Clemmons DR. Modulation of integrin antagonist signaling by ligand binding of the heparin-binding domain of vitronectin to the V3 integrin. J Cell Biochem. 2008;105:437-446.
53. Hocking DC, Sottile J, Reho T, Fassler R, McKeown-Longo PJ. Inhibition of fibronectin matrix assembly by the heparin-binding domain of vitronectin. J Biol Chem. 1999;274:27257-27264. (Pubitemid 129520256)
54. Hayashi M, Schlesinger DH, Kennedy DW, Yamada KM. Isolation and characterization of a heparin-binding domain of cellular fibronectin. J Biol Chem. 1980;255:10017-10020. (Pubitemid 11214576)
55. Yamada KM, Kennedy DW, Kimata K, Pratt RM. Characterization of fibronectin interactions with glycosaminoglycans and identification of active proteolytic fragments. J Biol Chem. 1980;255:6055-6063. (Pubitemid 10014217)